OCC Targeted Therapy & Immunotherapy in Oncology

Question 1

Which class of targeted therapy works by inhibiting the BCR-ABL tyrosine kinase, making it effective in chronic myeloid leukemia (CML)?

Accepted Answer

Tyrosine kinase inhibitors (TKIs)

Answer

Monoclonal antibodies

Answer

mTOR inhibitors

Answer

CDK 4/6 inhibitors

Question 2

Trastuzumab (Herceptin) targets which receptor overexpressed in HER2-positive breast cancer?

Accepted Answer

HER2/neu (ErbB2)

Answer

EGFR (HER1)

Answer

HER3

Answer

VEGFR-2

Question 3

What is the primary mechanism of action of bevacizumab (Avastin)?

Accepted Answer

Binds circulating VEGF to prevent tumor angiogenesis

Answer

Inhibits EGFR signaling on tumor cells

Answer

Blocks PD-1/PD-L1 immune checkpoint interaction

Answer

Inhibits mTOR complex 1 signaling

Question 4

KRAS mutations predict resistance to which targeted therapy in metastatic colorectal cancer?

Accepted Answer

Anti-EGFR agents such as cetuximab

Answer

Anti-VEGF agents such as bevacizumab

Answer

CDK 4/6 inhibitors such as palbociclib

Answer

ALK inhibitors such as crizotinib

Question 5

CDK 4/6 inhibitors such as palbociclib are approved in combination with endocrine therapy for which breast cancer subtype?

Accepted Answer

Hormone receptor-positive/HER2-negative breast cancer

Answer

Triple-negative breast cancer

Answer

HER2-positive breast cancer

Answer

Inflammatory breast cancer

Question 6

Which BRAF inhibitor is approved for BRAF V600E mutant unresectable melanoma?

Accepted Answer

Vemurafenib

Answer

Gefitinib

Answer

Erlotinib

Answer

Crizotinib

Question 7

The mTOR inhibitor everolimus is FDA-approved in combination with exemestane for which indication?

Accepted Answer

Advanced HR+/HER2- breast cancer after non-steroidal aromatase inhibitor failure

Answer

Advanced prostate cancer after enzalutamide failure

Answer

Metastatic colorectal cancer as second-line therapy

Answer

Renal cell carcinoma as first-line monotherapy only